The biological and economic value of oral organic iron in maintenance dialysis.
With the widespread use of recombinant erythropoietin (EPO) for patients with end-stage renal disease (ESRD), management of iron deficiency is an ongoing issue for the renal team. Effective iron replacement and maintenance play a vital role in efficient use of EPO. For hemodialysis patients, intravenous (i.v.) iron has proven convenient and, as an ancillary drug outside of the composite rate, generates profits for dialysis facilities. Improvements in the vehicle with which i.v. iron is administered have led to a reduction in severe or fatal reactions common with iron dextran products. Oral iron has had a spotty track record as an effective therapy for dialysis patients. Compliance has been hindered by patient discomfort when taking oral iron. Patients on peritoneal dialysis and those with chronic kidney disease remain good candidates for oral iron because of convenience, and oral formulas could prove more effective even in the hemodialysis patient population if they were better tolerated and better absorbed, and if using them would not place an economic burden on the patient and/or an economic hardship on the facility. In a capitated/bundled payment environment, oral iron may become a blessing rather than a curse for facilities that need to find more economic ways of providing services. Heme-iron, now undergoing clinical studies, may be a reliable replacement for i.v. iron in that scenario.
Wish
Jay B
JB
University Hospitals of Cleveland, Cleveland, Ohio, USA.
Fourtner
Pam
P
Ghaddar
Sana
S
Moore
Gary M
GM
D000284:Administration, Oral; D002204:Capitation Fee; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D007262:Infusions, Intravenous; D007349:Insurance, Health, Reimbursement; D007501:Iron / Q000191:economics / Q000627:therapeutic use*; D000090463:Iron Deficiencies; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy; D006435:Renal Dialysis / Q000009:adverse effects*
D007501:Iron